Track market-moving stories before they get noisy

In the latest close session, CRISPR Therapeutics AG (CRSP - Free Report) was down 2.08% at $46.54. This move lagged the S&P 500's daily gain of 0.05%. At the same time, the Dow added 0.46%, and the tech-heavy Nasdaq lost 0.64%.

The company's shares have seen a decrease of 11.95% over the last month, not keeping up with the Medical sector's gain of 3.64% and the S&P 500's gain of 0.61%.

The investment community will be closely monitoring the performance of CRISPR Therapeutics AG in its forthcoming earnings report. The company is expected to report EPS of -$1.1, up 14.73% from the prior-year quarter. At the same time, our most recent consensus estimate is projecting a revenue of $7.42 million, reflecting a 733.26% rise from the equivalent quarter last year.

CRSP's full-year Zacks Consensus Estimates are calling for earnings of -$4.9 per share and revenue of $28.88 million. These results would represent year-over-year changes of +24.27% and +722.82%, respectively.

Additionally, investors should keep an eye on any recent revisions to analyst forecasts for CRISPR Therapeutics AG. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the business and profitability.

Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.26% lower within the past month. CRISPR Therapeutics AG is currently a Zacks Rank #3 (Hold).

The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 91, finds itself in the top 37% echelons of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.

Posted by Defense World Staff on Jul 21st, 2026

Amova Asset Management Americas Inc. lessened its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 5.3% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,853,875 shares of the company’s stock after selling 104,236 shares during the quarter. CRISPR Therapeutics comprises approximately 1.2% of Amova Asset Management Americas Inc.’s holdings, making the stock its 26th biggest holding. Amova Asset Management Americas Inc. owned approximately 1.92% of CRISPR Therapeutics worth $88,189,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in CRSP. Hollencrest Capital Management increased its holdings in shares of CRISPR Therapeutics by 249.9% during the 1st quarter. Hollencrest Capital Management now owns 1,312 shares of the company’s stock worth $62,000 after buying an additional 937 shares during the last quarter. KBC Group NV boosted its holdings in CRISPR Therapeutics by 3,999.9% in the first quarter. KBC Group NV now owns 116,847 shares of the company’s stock valued at $5,558,000 after acquiring an additional 113,997 shares during the last quarter. Swiss National Bank grew its position in CRISPR Therapeutics by 5.1% during the first quarter. Swiss National Bank now owns 169,700 shares of the company’s stock valued at $8,073,000 after acquiring an additional 8,200 shares during the period. Allspring Global Investments Holdings LLC grew its position in CRISPR Therapeutics by 11.4% during the first quarter. Allspring Global Investments Holdings LLC now owns 5,932 shares of the company’s stock valued at $290,000 after acquiring an additional 605 shares during the period. Finally, Independent Financial Group LLC acquired a new stake in CRISPR Therapeutics during the first quarter worth about $292,000. 69.20% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at CRISPR Therapeutics In related news, insider Naimish Patel sold 3,786 shares of CRISPR Therapeutics stock in a transaction on Friday, May 29th. The shares were sold at an average price of $55.62, for a total transaction of $210,577.32. Following the sale, the insider owned 19,357 shares of the company’s stock, valued at $1,076,636.34. The trade was a 16.36% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 5.20% of the stock is owned by company insiders.

CRISPR Therapeutics Stock Down 1.7% NASDAQ CRSP opened at $46.99 on Tuesday. The company has a quick ratio of 17.96, a current ratio of 17.97 and a debt-to-equity ratio of 0.32. CRISPR Therapeutics AG has a fifty-two week low of $44.12 and a fifty-two week high of $78.48. The business has a 50 day moving average price of $52.96 and a two-hundred day moving average price of $52.88. The stock has a market cap of $4.53 billion, a PE ratio of -7.55 and a beta of 1.71.

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last posted its quarterly earnings data on Tuesday, March 31st. The company reported ($1.28) earnings per share (EPS) for the quarter. The firm had revenue of $1.46 million for the quarter. CRISPR Therapeutics had a negative net margin of 13,856.54% and a negative return on equity of 25.66%. As a group, sell-side analysts predict that CRISPR Therapeutics AG will post -4.9 EPS for the current fiscal year.

Analysts Set New Price Targets A number of equities analysts have recently commented on the company. Wall Street Zen downgraded CRISPR Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, July 5th. Citizens Jmp reissued a “market outperform” rating and set a $80.00 target price on shares of CRISPR Therapeutics in a research report on Monday, July 6th. Weiss Ratings restated a “sell (d-)” rating on shares of CRISPR Therapeutics in a report on Friday. Evercore reaffirmed an “outperform” rating and set a $76.00 price target on shares of CRISPR Therapeutics in a research report on Monday, May 11th. Finally, UBS Group set a $80.00 price objective on shares of CRISPR Therapeutics in a research note on Friday, June 12th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, CRISPR Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $67.78.

Check Out Our Latest Report on CRISPR Therapeutics

About CRISPR Therapeutics (Free Report)

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.

Featured Articles Five stocks we like better than CRISPR Therapeutics The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAlTi Global Inc. Sells 1,847 Shares of Vanguard Small-Cap ETF $VB

NEXT HEADLINE »10x Genomics $TXG Shares Sold by Amova Asset Management Americas Inc.

In the latest trading session, CRISPR Therapeutics AG (CRSP - Free Report) closed at $47.78, marking a -1.63% move from the previous day. This change lagged the S&P 500's 1.01% loss on the day. Meanwhile, the Dow lost 0.77%, and the Nasdaq, a tech-heavy index, lost 1.4%.

Shares of the company have depreciated by 10.21% over the course of the past month, underperforming the Medical sector's gain of 5.37%, and the S&P 500's gain of 0.32%.

Analysts and investors alike will be keeping a close eye on the performance of CRISPR Therapeutics AG in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of -$1.1, marking a 14.73% rise compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $7.42 million, showing a 733.26% escalation compared to the year-ago quarter.

For the annual period, the Zacks Consensus Estimates anticipate earnings of -$4.9 per share and a revenue of $28.88 million, signifying shifts of +24.27% and +722.82%, respectively, from the last year.

It is also important to note the recent changes to analyst estimates for CRISPR Therapeutics AG. Such recent modifications usually signify the changing landscape of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.

Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.26% lower within the past month. As of now, CRISPR Therapeutics AG holds a Zacks Rank of #3 (Hold).

The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 93, putting it in the top 38% of all 250+ industries.

The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow CRSP in the coming trading sessions, be sure to utilize Zacks.com.

CRISPR Therapeutics AG (CRSP - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Over the past month, shares of this company have returned -3.8%, compared to the Zacks S&P 500 composite's +1.3% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which CRISPR Therapeutics falls in, has gained 3.6%. The key question now is: What could be the stock's future direction?

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.

Revisions to Earnings EstimatesRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.

We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

CRISPR Therapeutics is expected to post a loss of $1.10 per share for the current quarter, representing a year-over-year change of +14.7%. Over the last 30 days, the Zacks Consensus Estimate remained unchanged.

The consensus earnings estimate of -$4.89 for the current fiscal year indicates a year-over-year change of +24.4%. This estimate has changed -0.1% over the last 30 days.

For the next fiscal year, the consensus earnings estimate of $3.97 indicates a change of +18.8% from what CRISPR Therapeutics is expected to report a year ago. Over the past month, the estimate has remained unchanged.

Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, CRISPR Therapeutics is rated Zacks Rank #3 (Hold).

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Projected Revenue GrowthEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.

In the case of CRISPR Therapeutics, the consensus sales estimate of $7.42 million for the current quarter points to a year-over-year change of +733.3%. The $28.88 million and $131.2 million estimates for the current and next fiscal years indicate changes of +722.8% and +354.3%, respectively.

Last Reported Results and Surprise HistoryCRISPR Therapeutics reported revenues of $1.46 million in the last reported quarter, representing a year-over-year change of +67.8%. EPS of -$1.28 for the same period compares with -$1.58 a year ago.

Compared to the Zacks Consensus Estimate of $8.39 million, the reported revenues represent a surprise of -82.62%. The EPS surprise was -12.28%.

Over the last four quarters, CRISPR Therapeutics surpassed consensus EPS estimates two times. The company topped consensus revenue estimates times over this period.

ValuationWithout considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.

While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.

The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

CRISPR Therapeutics is graded F on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about CRISPR Therapeutics. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.

CRISPR Therapeutics (CRSP 4.99%) has significantly underperformed broader equities over the past five years. Some will argue the company's value -- its market cap is $5.7 billion as of writing -- is still too high given the fundamentals of the business. CRISPR Therapeutics generates little revenue, is consistently unprofitable, and hasn't earned significant late-stage clinical wins over the past couple of years. However, despite all that, CRISPR Therapeutics could be an attractive buy-and-hold option. Let's consider three reasons why the biotech is worth serious consideration.

1. Multiple catalysts on the way CRISPR Therapeutics specializes in developing gene editing therapies. This technology has already helped unlock groundbreaking medicines for otherwise difficult-to-treat conditions. However, we are arguably still in the early innings of the gene-editing revolution in the biotech industry, as the U.S. Food and Drug Administration has approved only a few treatments of this kind. But thanks to its potential to transform standards of care across many therapeutic areas, it's worth investors' time to look for the best gene-editing-focused companies. CRISPR Therapeutics fits the bill.

Image source: The Motley Fool.

The biotech's lineup features several promising candidates that could make significant progress over the next few years, jolting its stock price. Consider CRISPR Therapeutics' CTX310, an investigational one-time treatment designed to permanently lower LDL cholesterol by switching off the ANGPTL3 gene (which helps regulate cholesterol) in the liver, helping the body remove harmful fats from the bloodstream more effectively. If it proves safe and effective, it could transform care by replacing lifelong cholesterol drugs with a one-time treatment. With millions of people at high risk of heart disease (and other cardiovascular conditions) due to high cholesterol levels, CTX310 has a potentially large commercial opportunity.

CRISPR Therapeutics plans on releasing results from an ongoing clinical trial of CTX310 during the second half of the year. Positive data could send CRISPR Therapeutics' shares soaring. And that's just the tip of the iceberg. CRISPR Therapeutics has other promising candidate that should also make progress in the next few years. The biotech's strong, gene-editing-focused pipeline makes the stock attractive, as the company's breakthrough could lead to highly effective treatments and significant commercial success.

2. Casgevy's large opportunity CRISPR Therapeutics has already shown it can secure approval for a gene-editing medicine. It did so with Casgevy, a therapy for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed with Vertex Pharmaceuticals (VRTX 2.07%). This may seem trivial, but the fact is that many (perhaps most) of CRISPR Therapeutics' peers -- that is, biotechs that specialize in gene editing -- have yet to earn approval for a single one of their candidates. Also, Casgevy's milestone was all the more impressive because it was the first CRISPR-based gene-editing therapy to receive regulatory approval.

Today's Change

(

-4.99

%) $

-2.81

Current Price

$

53.53

Casgevy has not yet generated much revenue, but that could change soon. CRISPR Therapeutics and Vertex Pharmaceuticals recently announced that the U.S. Food and Drug Administration had approved the medicine for children as young as two (it was previously indicated for people aged 12 and older). This label expansion adds 5,500 patients to Casgevy's addressable market in the country.

That may not seem like a lot, but at $2.2 million per treatment course, that's an additional $12.1 billion commercial opportunity, and that's only in the U.S. (Vertex and CRISPR Therapeutics share the earnings from Casgevy, with the latter getting 40% of the profits). Casgevy won't capture this entire market on its own, but the medicine's sales should ramp up over the next few years, helping boost CRISPR Therapeutics' financial results.

3. Expanding beyond gene editing Although gene editing remains CRISPR Therapeutics' core focus, the company has branched out into other areas. The biotech partnered with Sirius Therapeutics, a privately held company, to develop CTX611, a small-interfering RNA (siRNA) therapy. Unlike gene-editing medicines that alter the DNA sequence, siRNA medicines "silence" genes responsible for certain diseases, though the effect is temporary, and these therapies need to be readministered.

CTX611 is a long-acting siRNA therapy designed to prevent dangerous blood clots while causing less bleeding than today's anticoagulants. If approved, its potential for just two injections per year could make it a transformative treatment and a multibillion-dollar commercial success. Just as important, CRISPR Therapeutics is showing that it isn't just a gene editing company. The biotech is willing to pursue attractive opportunities in other fields.

Read the fine print A lot could still go wrong with CRISPR Therapeutics, particularly significant clinical setbacks for its most promising candidates. The company's commercial opportunity with Casgevy could also fail to materialize. These are all risks investors should keep in mind. However, given its partnership with a biotech giant to commercialize Casgevy and its deep (and innovative) pipeline, CRISPR Therapeutics looks likely to significantly expand its approved product portfolio and improve its financial results by the end of the decade. The stock may offer outstanding returns along the way.

Like most other up-and-coming biopharma companies, CRISPR Therapeutics (CRSP 2.10%) brings both risk and reward to the table. This particular name, however, may bring less risk than it seems at first blush, and perhaps even more reward.

CRISPR Therapeutics is different from most of its kind CRISPR Therapeutics is a developer of gene therapies for disease, by the way. Specifically, the company's founders figured out how to cut a damaged segment out of a DNA strand and replace it with a corrected one. It even has an approved therapy on the market, with more in the works.

As you might imagine, though, such development isn't cheap. Like other newcomers to the biopharma business, CRISPR Therapeutics is consuming cash at a pretty brisk clip.

Image source: Getty Images.

However, it's different from most others of this ilk. Unlike its similarly sized and similarly aged peers, this $5.9 billion outfit is sitting on $2.4 billion worth of cash and marketable securities that can be readily converted into cash if and when the need arises. At its current rate of cash burn, that's a little over four years' worth of funding without the need for any additional, dilutive fund-raising.

This essentially means the company's science, research, and future are currently valued at only about $3.5 billion, or only around $3 billion after factoring in debt.

The stock price reflects too much risk with not enough reward Granted, CRISPR Therapeutics needs at least some of its current research and development pipeline to result in drug approvals to justify any valuation. And to raise money, the company has issued stock and convertible notes before, which of course was dilutive.

Today's Change

(

-2.10

%) $

-1.30

Current Price

$

60.59

All of this is already priced into the stock, though, and won't need to happen again anytime soon -- if ever. See, CRISPR Therapeutics has the potential to generate its own self-sustaining funding within just a few years. The odds of this happening aren't reflected in the current share price.

Analysts don't think so, anyway. Their current consensus price target of $81.10 is 35% above the price right now.

CRSP weekly chart shows completion of bearish correction within long-term bull trend

Next Resistance Could Unlock Trend Reversal Friday’s advance confirmed breakouts from both bottoming patterns, with initial resistance seen near the February swing high of $61.76. Once that February high is decisively recovered, another bullish signal would be triggered, as that would indicate that the prior intermediate downtrend has reversed. It would also provide further confirmation that the broader bottoming process has completed, signaling the beginning of a new leg higher within the long-term bull trend.

Measured Move Targets Extend Bullish Outlook CRSP reached a high of $78.48 in October 2025, completing a 54.5% gain from the prior swing low recorded in September. Projecting a similar measured move from the March low of $44.12 points to a potential upside target near $67.94. In addition, the inverse head and shoulders pattern projects upside objectives of approximately $75.61 using a traditional price objective or $81.18 using an equivalent percentage advance. Those targets reinforce the significance of the recent breakout and suggest it could mark the early stages of a larger bullish trend reversal, provided the breakout continues to hold.

If you’d like to know more about technical analysis and how traders use it, please visit our educational area.

Choosing between Arcutis Biotherapeutics (ARQT 0.12%) and Vertex Pharmaceuticals (VRTX +6.13%) involves weighing a high-growth newcomer against a cash-generating giant. Both companies aim to dominate their respective niches within the healthcare sector.

Arcutis focuses on topical treatments for common skin conditions, aiming to disrupt the competitive dermatology market with innovative creams. Vertex is a global leader in treating rare diseases, recently diversifying its portfolio beyond its core cystic fibrosis treatments. Both companies represent different risk-reward profiles for investors targeting the biotech space.

The case for Arcutis BiotherapeuticsArcutis Biotherapeutics is a commercial-stage medical dermatology company that develops and sells topical therapies for immune-mediated skin diseases. Its primary commercial strategy centers on the Zoryve product line, which includes treatments for plaque psoriasis and atopic dermatitis. To reach patients, the company relies on a network of specialty pharmacies and maintains strategic licensing agreements with AstraZeneca (AZN +6.04%) and Jiangsu Hengrui Medicine.

In FY 2025, revenue reached nearly $376.1 million, representing a massive 101% growth over the prior year. Despite this rapid expansion, the company reported a net loss of $16.1 million. This net loss is a significant improvement over the prior year’s $140 million loss, suggesting the company is effectively scaling its revenue relative to its fixed costs.

On its current balance sheet, the debt-to-equity ratio is close to 0.7x, showing a strong ability to cover short-term liabilities with current assets. Free cash flow was a negative $6.3 million as the business continues to invest in its growth within the biotech stocks landscape.

The case for Vertex PharmaceuticalsVertex Pharmaceuticals is a global biotechnology leader primarily known for its dominance in treating cystic fibrosis. The company derives nearly all of its product revenue from medicines like Trikafta, which it distributes through a limited number of specialty pharmacy networks. It also maintains key strategic collaborations with CRISPR Therapeutics (CRSP +7.77%) and Moderna (MRNA +9.99%) to develop new therapies for serious diseases like sickle cell disease.

In FY 2025, revenue reached $12 billion, representing a year-over-year increase of nearly 10%. The company reported net income of nearly $4 billion, resulting in a net margin of approximately 32.7%. Net margin indicates how much of every dollar in revenue actually becomes profit after all expenses, and the company's P/S ratio, which compares its stock price to its total sales, reflects its market standing.

Its current debt-to-equity ratio is approximately 0.1x. This ratio compares total debt to shareholder equity, and a lower number indicates a conservative approach to borrowing. Free cash flow for FY 2025 was close to $3.2 billion. Free cash flow is the cash a company generates after accounting for the money spent to maintain or expand its asset base.

Risk profile comparisonArcutis Biotherapeutics faces substantial risks stemming from its reliance on the Zoryve product line in a competitive field dominated by giants like AbbVie (ABBV +3.90%) and Pfizer (PFE +1.84%). Additionally, the company is involved in patent litigation with Teva Pharmaceutical Industries (TEVA +3.59%) regarding generic versions of its flagship cream. Failure to protect its intellectual property or meet financial covenants with SLR Investment Corp (SLRC 0.72%) could significantly harm its operations.

Vertex Pharmaceuticals deals with heavy revenue concentration, as its cystic fibrosis franchise accounts for the vast majority of its sales. This makes the company vulnerable to competitive entry and ongoing pricing pressure from government cost-containment measures like the Inflation Reduction Act. Clinical development also carries inherent risks, as illustrated by a recent class-action investigation into results from a Phase 2b trial.

Valuation comparisonVertex Pharmaceuticals offers a lower Forward P/E, but Arcutis Biotherapeutics has a lower P/S ratio compared to its peer.

MetricArcutis BiotherapeuticsVertex PharmaceuticalsSector BenchmarkForward P/E142.86x26.1x389.1xP/S ratio8.0x10.5xSector benchmark uses the SPDR XLV sector ETF.
Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.

Arcutis has just reached positive cash flow in its first quarter of fiscal 2026, with sales up 65% from the first quarter of 2025 but down 16% sequentially. This stems from the fact Zoryve isn’t a must-have for most patients, so its demand appeared impacted by higher consumer costs from rising gas prices and food inflation. The company discounts the product price, covers the copay if the patient has insurance, and charges $35 if they don’t. Demand for Zoryve also seems to be driven by the weather, with demand weaker when the weather doesn’t trigger as many skin conditions.

The cash-flow positive quarter means the business does have the capital to start to invest more in marketing and promoting Zoryve. Research and development efforts should lead to more indications that Zoryve can treat, too. Wall Street sees revenue rising 26% this year to $497 million, with the business registering its first annual net income.

Vertex, meanwhile, is building on its dominant position in cystic fibrosis treatment by investing heavily in research and development. In the past couple of years, Vertex has expanded its CF drug treatments. Its products now address 95% of all CF patients in the U.S. Approvals in other markets are coming through, which means the market for its existing drugs continues to expand. Vertex is also deep in trials for a drug to treat conditions that lead to renal failure, a new market for Vertex. The U.S. has accelerated approval for povetacicept in IgA nephropathy, a treatment that would be a blockbuster ($1 billion-plus in lifetime sales) if approved.

Arcutis is an interesting business that is just getting off the ground. Yet Arcutis’ main product does not fill a high-priced niche and appears subject to seasonality and fluctuations in consumer demand, which should give an investor pause.

Vertex continues to be a fast grower too, with Wall Street seeing sales grow more than $1 billion this year to over $13 billion, with nearly $4.5 billion in net income. With an expanding market, heavy R&D, and a decent price-to-forward earnings ratio, Vertex gets the nod.

Deciding between CRISPR Therapeutics AG (CRSP +1.74%) and Vertex Pharmaceuticals (VRTX +2.31%) involves weighing high-growth gene-editing potential against a profitable, established leader. Both companies currently partner on breakthrough therapies but offer different investor profiles.

CRISPR Therapeutics focuses on transformative gene-based medicines, while Vertex dominates the cystic fibrosis market and generates substantial cash flow. They share the profits of their joint gene-editing therapy, CASGEVY. This comparison evaluates their financial health, risk factors, and current valuations to help you decide which fits your portfolio strategy better.

CRISPR Therapeutics AG focuses on creating transformative medicines through its proprietary gene-editing platform. Its flagship product is CASGEVY, a therapy developed for sickle cell disease and transfusion-dependent beta thalassemia. The company relies heavily on its partnership with Vertex Pharmaceuticals, sharing profits and losses at a 40% to 60% split. This customer concentration adds a layer of risk to the business since the company maintains limited internal commercial infrastructure and relies on the global footprint of its partner.

In FY 2025, revenue reached nearly $3.5 million, representing a decline of roughly 90.0% compared to the prior year. This decrease occurred as the company transitioned through different stages of milestone recognition and commercial rollout. The company reported a net loss of approximately $581.6 million for the period, reflecting the heavy investment required for its clinical pipeline. High net losses are typical for biotech stocks pursuing groundbreaking medical advancements.

According to its December 2025 balance sheet, the debt-to-equity ratio is roughly 0.2x. This indicates that the company has a low level of total debt compared to the equity held by shareholders. The current ratio, which measures the ability to pay short-term obligations with short-term assets, is approximately 13.3x. Free cash flow was negative at nearly $345.9 million, as the company prioritized research over cash generation.

The case for Vertex PharmaceuticalsVertex Pharmaceuticals provides essential treatments for serious diseases, primarily dominating the global market for cystic fibrosis therapies. Its portfolio includes widely used medicines like TRIKAFTA and ALYFTREK, alongside its newer acute pain medication, JOURNAVX. The company operates through a global distribution network of wholesalers and specialty pharmacies. It also leads the commercialization of CASGEVY in its partnership with CRISPR Therapeutics AG.

For FY 2025, the company generated revenue of close to $12 billion, a year-over-year increase of roughly 8.9%. Net income reached approximately $4.0 billion, demonstrating the company's ability to maintain high profitability from its established drug portfolio. The net margin was roughly 32.7%, illustrating the significant portion of revenue that remains after all expenses are paid. These figures highlight a mature business model with steady cash inflows and consistent growth.

As of its December 2025 balance sheet, the debt-to-equity ratio was approximately 0.4x. A low ratio suggests the company is not overly dependent on borrowed money to fund its operations. The current ratio stands at roughly 2.9x, indicating a healthy margin of safety for meeting short-term financial commitments. Free cash flow, calculated as cash from operations minus capital expenditures, was strong at nearly $3.2 billion.

Risk profile comparisonCRISPR Therapeutics AG faces significant hurdles regarding its financial sustainability, having incurred substantial operating losses that require frequent capital raises. One such raise included a $600 million convertible note issuance in Q1 2026. The company also faces intellectual property litigation from ToolGen, which alleges patent infringement by its core gene-editing technology. Furthermore, any disruption in its relationship with its primary partner could materially harm its commercial prospects and long-term viability.

Vertex Pharmaceuticals deals with heavy revenue concentration, as the vast majority of its sales come from its cystic fibrosis portfolio. This makes the business vulnerable to new competitive launches or regulatory actions affecting those specific drugs. Clinical setbacks, such as the RewinD-LB trial failure, remind investors of the inherent risks in drug development. Additionally, the company faces pressure from federal initiatives like the Inflation Reduction Act and legal arbitration with the Cystic Fibrosis Foundation over royalty costs.

Valuation comparisonVertex Pharmaceuticals trades at a lower revenue multiple than its younger peer, though its earnings valuation sits closer to the broader sector average.

MetricCRISPR Therapeutics AGVertex PharmaceuticalsSector BenchmarkForward P/E18.6x25.3x24.6xP/S ratio1270x10xn/aSector benchmark uses the SPDR XLV sector ETF.
Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.

Which stock would I buy in 2026?These two stocks require completely different investor mindsets, and the choice between them is less about which is better and more about what you're trying to do. Vertex is a profitable, cash-generating business with a dominant market position and a pipeline expanding beyond cystic fibrosis. It rewards patience without demanding it — the kind of stock that quietly compounds while you're watching something else. CRISPR is a different proposition entirely. You're betting on a technology platform still proving itself, with real clinical shots on goal but no earnings and a long road to commercial independence. The upside is asymmetric if the pipeline delivers; so is the downside if it doesn't. An investor who wants durable healthcare exposure without binary outcomes owns Vertex. A risk-tolerant investor with a long horizon and conviction in gene editing has a case for CRISPR. And if you want both ends of the spectrum, together they form a natural barbell for a healthcare allocation — a profitable compounder paired against a high-risk platform bet.

If you're getting started with investing or want ideas on which stocks could be good buys in today's market, let me walk you through how I'd invest $10,000 today.

What I think is important is to create some strong pillars in your portfolio, around blue chip stocks that you don't have to worry about. This gives you a good base and foundation where you put the bulk of your money into. This is likely where you'll also want to have some dividend income, just to pad your returns or generate valuable cash flow (should you decide not to reinvest the dividends). And after doing this, you can then take on some risk and potentially capitalize on lucrative opportunities in the long run.

Here's how I'd allocate $10,000 using this approach.

Image source: Getty Images.

I'd put $6,000 into a top dividend stock For a rock-solid base to build around, I'd pick Enbridge (ENB +0.15%) stock. The company has been growing its dividend for decades, has a stable, consistent pipeline business, and already offers a fairly high yield of 5%. It's an absolute gem in the oil and gas sector, yet it doesn't come with the risk that often accompanies these types of stocks. Since it's involved in infrastructure and transporting oil and gas, it's a much safer all-around investment to consider.

Today's Change

(

0.15

%) $

0.08

Current Price

$

54.55

This year, the stock has performed particularly well, up 16%, as investors have been loading up on oil and gas stocks amid rising commodity prices. But Enbridge is a solid stock to own, regardless of the price of oil. It has averaged a beta of 0.81 over the past five years, indicating that it's less volatile than the overall stock market. With a safe dividend and a robust business, I'd feel comfortable investing $6,000 in the stock, which, based on the current yield, would produce about $300 in dividends per year.

I'd invest $3,000 into an excellent growth stock As part of a long-term growth strategy, I'd also want to put a fair bit of money into a promising growth stock. But I don't want to put my money at risk and throw it at just any growth stock. Instead, I'd put it in a leading company such as Alphabet (GOOG +1.58%)(GOOGL +1.29%).

Alphabet stands out for its diversification and financial strength. Between YouTube, Google Search, Gemini, and Waymo, the company has promising assets that can drive growth for years to come. It offers the type of diversification you might crave in an exchange-traded fund, yet you get it through a single stock.

Today's Change

(

1.58

%) $

5.72

Current Price

$

367.82

The company has a wealth of resources to tap into that can enable it to pursue more acquisitions in the future or simply reinvest in its current operations. Alphabet has generated a staggering $160 billion in profit over the past four quarters. Its business is growing, and its margins are impressive. This is the type of low-risk growth stock that can also make for an excellent long-term investment.

The last $1,000 I'd reserve for a stock with a bit more risk but a ton of upside Now, with a couple of solid blue chip stocks in Alphabet and Enbridge, I can feel comfortable in taking on a bit more risk with the remaining $1,000. While I still don't want to gamble on highly speculative investments, I do want to focus on a much smaller business that may have significant growth potential.

For this stock, I'd choose CRISPR Therapeutics (CRSP +1.88%). CRISPR has a market cap of $5 billion and could be much more valuable in the future. It and its development partner, Vertex Pharmaceuticals, have an approved gene-editing therapy, Casgevy, which is in its early stages of commercialization. Thus, CRISPR isn't as risky as smaller biotech stocks without any approved products. It also has over $2 billion in cash and short-term investments to help fund its day-to-day operations, and also enable it to invest in other gene-editing therapies.

Today's Change

(

1.88

%) $

1.00

Current Price

$

54.09

CRISPR remains unprofitable, but it has some enticing growth opportunities. And I'd feel confident that even under a worst-case scenario where I lose most or all of my money in CRISPR, I could make it back through my other investments on this list. By having strong pillars in place, you can take on some risk while knowing you won't put your overall portfolio in serious danger.

CRISPR Therapeutics AG (CRSP - Free Report) ended the recent trading session at $53.09, demonstrating a +2.06% change from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily loss of 1.22%. Meanwhile, the Dow lost 0.98%, and the Nasdaq, a tech-heavy index, lost 1.35%.

The stock of company has risen by 9.31% in the past month, leading the Medical sector's gain of 4.11% and the S&P 500's gain of 1.56%.

The investment community will be paying close attention to the earnings performance of CRISPR Therapeutics AG in its upcoming release. The company is predicted to post an EPS of -$1.13, indicating a 12.4% growth compared to the equivalent quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $7.42 million, showing a 733.26% escalation compared to the year-ago quarter.

CRSP's full-year Zacks Consensus Estimates are calling for earnings of -$4.89 per share and revenue of $28.88 million. These results would represent year-over-year changes of +24.42% and +722.82%, respectively.

Investors should also pay attention to any latest changes in analyst estimates for CRISPR Therapeutics AG. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.

Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.

The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has moved 4.26% higher. Currently, CRISPR Therapeutics AG is carrying a Zacks Rank of #3 (Hold).

The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 150, positioning it in the bottom 39% of all 250+ industries.

The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.

CRISPR Therapeutics AG (CRSP - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Over the past month, shares of this company have returned +8.3%, compared to the Zacks S&P 500 composite's +2.1% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which CRISPR Therapeutics falls in, has gained 1.1%. The key question now is: What could be the stock's future direction?

While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.

Earnings Estimate RevisionsHere at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.

Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.

CRISPR Therapeutics is expected to post a loss of $1.13 per share for the current quarter, representing a year-over-year change of +12.4%. Over the last 30 days, the Zacks Consensus Estimate has changed -1.7%.

For the current fiscal year, the consensus earnings estimate of -$4.89 points to a change of +24.4% from the prior year. Over the last 30 days, this estimate has changed +4.3%.

For the next fiscal year, the consensus earnings estimate of $3.97 indicates a change of +18.9% from what CRISPR Therapeutics is expected to report a year ago. Over the past month, the estimate has changed -9.4%.

Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, CRISPR Therapeutics is rated Zacks Rank #3 (Hold).

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Projected Revenue GrowthEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.

For CRISPR Therapeutics, the consensus sales estimate for the current quarter of $7.42 million indicates a year-over-year change of +733.3%. For the current and next fiscal years, $28.88 million and $131.2 million estimates indicate +722.8% and +354.3% changes, respectively.

Last Reported Results and Surprise HistoryCRISPR Therapeutics reported revenues of $1.46 million in the last reported quarter, representing a year-over-year change of +67.8%. EPS of -$1.28 for the same period compares with -$1.58 a year ago.

Compared to the Zacks Consensus Estimate of $8.39 million, the reported revenues represent a surprise of -82.62%. The EPS surprise was -12.28%.

Over the last four quarters, CRISPR Therapeutics surpassed consensus EPS estimates two times. The company topped consensus revenue estimates times over this period.

ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.

Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.

As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

CRISPR Therapeutics is graded F on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about CRISPR Therapeutics. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.

3 Biotech Stocks That Could Benefit from the Patent CliffCRISPR Therapeutics NASDAQ: CRSP Chief Executive Officer Sam Kulkarni said the company is entering a “second phase” as it moves beyond the initial launch of CASGEVY and prepares for data from multiple pipeline programs over the next 12 to 18 months.

Speaking at a Bank of America fireside chat hosted by analyst Alec Stranahan, Kulkarni said the company’s first 11 years were centered on developing CASGEVY for sickle cell disease and beta thalassemia and bringing the therapy to patients. With that program now commercialized through partner Vertex, he said CRISPR Therapeutics is shifting more attention to a broader portfolio that includes cardiovascular, autoimmune, oncology and rare disease programs.

Get CRISPR Therapeutics alerts:

CRISPR Therapeutics Gains After Earnings as Pipeline Hope GrowsKulkarni said the company expects six assets to generate data in the next 12 to 18 months. He described the pipeline as including CTX310, an ANGPTL3-targeting program for LDL cholesterol and triglyceride reduction; zugo-cel, an allogeneic CAR T cell therapy being developed for autoimmune disease and oncology; CTX611, a long-acting siRNA approach to blood thinning; CTX340, a hypertension program targeting angiotensinogen; an Lp(a) program; and an alpha-1 antitrypsin rare disease program.

CASGEVY Launch Gains Momentum, CEO Says Kulkarni said CASGEVY’s commercial rollout is “gaining a lot of momentum,” though he emphasized that the launch differs from a typical pharmaceutical launch because of the time required between patient initiation, cell collection, manufacturing, infusion and revenue recognition.

CRSPR Stock Could Be Ready to Deliver on Its Massive PromiseHe said Vertex, which is leading commercialization, initiated about 100 patients in 2024, more than 300 patients in 2025 and has now initiated more than 500 patients. Kulkarni said the growth in patient initiations should translate into future revenue as patients move through the treatment funnel, though he noted there can be a lag of two to three quarters from initiation to revenue recognition.

“It’s a certainty that it all falls through because you’re not seeing patients drop out of the journey,” Kulkarni said. “It’s just a matter of time.”

Stranahan noted that CASGEVY generated $43 million in the first quarter. Kulkarni said CRISPR Therapeutics does not see major headwinds for the product at this stage and said Vertex is executing well on supply chain and patient handling. He said the company feels “comfortable about the trajectory of the product.”

Pediatric Label and Reimbursement Seen as Tailwinds Kulkarni pointed to several potential tailwinds for CASGEVY, including a pediatric label expansion. The current U.S. label covers patients ages 12 and older, and the company has submitted for an expansion to patients ages 5 and older. Kulkarni said treating younger patients could help prevent vascular and organ damage associated with disease progression.

He also said the pediatric expansion could bring more children’s hospitals into the treatment network, potentially increasing center activation and treatment velocity.

Outside the United States, Kulkarni said CASGEVY is the only available option in certain markets. He also highlighted a reimbursement agreement in Germany, describing it as a significant achievement given prior challenges faced by a competitor in that market.

Kulkarni also discussed “gentler conditioning” as a future potential expansion of CASGEVY’s life cycle. He said CRISPR Therapeutics has not provided guidance on when such an approach might be available, but said it could meaningfully broaden the addressable population if it achieves results comparable to the current busulfan conditioning regimen.

Cardiovascular Programs Target Large Markets On CTX310, Kulkarni said the company presented data last year showing reductions of approximately 50% in LDL cholesterol or triglycerides after treatment. He said the therapy uses lipid nanoparticle delivery and described the early safety profile as favorable, with limited and self-resolving liver enzyme elevations observed.

For homozygous familial hypercholesterolemia, Kulkarni said the regulatory bar could be relatively low if the therapy can show additional LDL reduction on top of agents such as PCSK9 inhibitors. For severe hypertriglyceridemia, he said CRISPR Therapeutics needs more patient data before engaging regulators on a potential registrational path.

Kulkarni also discussed CTX340, which targets angiotensinogen for hypertension. He said a gene-editing approach could provide consistent blood pressure reduction, in contrast to therapies that may wear off toward the end of a dosing period. He said reducing systolic blood pressure by 10 to 15 millimeters of mercury could be clinically meaningful, while still allowing physicians to adjust other medications.

Separately, Kulkarni said the company’s collaboration with Sirius Therapeutics on a Factor XI siRNA program reflects a “right tool for the job” approach. He said CRISPR Therapeutics does not want to permanently edit Factor XI because anticoagulation may be needed for defined periods or specific patient populations. He said the company sees potential indications including secondary stroke prevention, atrial fibrillation patients not eligible for DOACs and peripheral artery disease after revascularization.

Zugo-cel Advances in Autoimmune Disease and Oncology Kulkarni described zugo-cel as a potential best-in-class allogeneic CD19 CAR T therapy, citing what he called autologous-like efficacy with the convenience and cost-of-goods profile of an allogeneic product.

In oncology, he said CRISPR Therapeutics previously showed a nearly 70% complete response rate, with at least two patients beyond 12 months at the time of the data cut. The company is also studying zugo-cel in combination with the BTK inhibitor pirtobrutinib, based on evidence that BTK inhibitors may potentiate CAR T therapies.

In autoimmune disease, Kulkarni said the company’s goal is to become a leading player. CRISPR Therapeutics has dosed patients in lupus, myositis and scleroderma through the AID-500 trial and has expanded into immune thrombocytopenia and warm autoimmune hemolytic anemia. He said the company has also opened an IND for neuroimmune indications, citing evidence that zugo-cel can enter the central nervous system and eliminate B cells in the spine or brain.

Kulkarni said CRISPR Therapeutics had dosed 14 patients in its autoimmune program as of its first-quarter update and expects to provide additional updates as development progresses.

About CRISPR Therapeutics NASDAQ: CRSPCRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in CRISPR Therapeutics Right Now?Before you consider CRISPR Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list.

While CRISPR Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Click the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

CRISPR Therapeutics AG (CRSP - Free Report) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.

Over the past month, shares of this company have returned -15.8%, compared to the Zacks S&P 500 composite's +4% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which CRISPR Therapeutics falls in, has lost 7.8%. The key question now is: What could be the stock's future direction?

While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.

Earnings Estimate RevisionsRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.

Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.

For the current quarter, CRISPR Therapeutics is expected to post a loss of $1.12 per share, indicating a change of +13.2% from the year-ago quarter. The Zacks Consensus Estimate has changed +5.7% over the last 30 days.

The consensus earnings estimate of -$5.08 for the current fiscal year indicates a year-over-year change of +21.5%. This estimate has changed -3.2% over the last 30 days.

For the next fiscal year, the consensus earnings estimate of $4.37 indicates a change of +14.1% from what CRISPR Therapeutics is expected to report a year ago. Over the past month, the estimate has changed +4%.

Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, CRISPR Therapeutics is rated Zacks Rank #3 (Hold).

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Revenue Growth ForecastEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.

In the case of CRISPR Therapeutics, the consensus sales estimate of $8.08 million for the current quarter points to a year-over-year change of +808.1%. The $34.6 million and $129.51 million estimates for the current and next fiscal years indicate changes of +885.6% and +274.4%, respectively.

Last Reported Results and Surprise HistoryCRISPR Therapeutics reported revenues of $1.46 million in the last reported quarter, representing a year-over-year change of +67.8%. EPS of -$1.28 for the same period compares with -$1.58 a year ago.

Compared to the Zacks Consensus Estimate of $8.39 million, the reported revenues represent a surprise of -82.62%. The EPS surprise was -12.28%.

Over the last four quarters, CRISPR Therapeutics surpassed consensus EPS estimates two times. The company topped consensus revenue estimates times over this period.

ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.

While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.

The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

CRISPR Therapeutics is graded F on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about CRISPR Therapeutics. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.

May 28, 2026 08:00 ET  | Source: CRISPR Therapeutics AG

ZUG, Switzerland and BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team are scheduled to participate in the following investor conferences in June.

Jefferies Global Healthcare Conference
Date: Wednesday, June 3, 2026
Time: 9:55 a.m. ET

William Blair’s 46th Annual Growth Stock Conference
Date: Wednesday, June 3, 2026
Time: 4:40 p.m. CT

Goldman Sach’s 47th Annual Global Healthcare Conference
Date: Tuesday, June 9, 2026
Time: 2:40 p.m. ET

A live webcast will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcasts will be archived on the Company's website for 14 days following the presentation.

About CRISPR Therapeutics
CRISPR Therapeutics is a leading biopharmaceutical company focused on developing transformative gene-based medicines for serious human diseases. Founded over a decade ago as an early pioneer in CRISPR/Cas9 gene editing, the Company has evolved from a pioneering research-stage organization into an industry leader, marking a historic milestone with the approval of CASGEVY® (exagamglogene autotemcel [exa-cel]), the world’s first CRISPR-based therapy, for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia. Today, CRISPR Therapeutics is advancing a broad, diversified pipeline spanning hemoglobinopathies, cardiovascular disease, autoimmune disease, oncology, regenerative medicine and rare diseases. The Company is also expanding its gene editing toolkit through SyNTase™ editing, its novel, proprietary platform designed to enable precise, efficient, and scalable gene correction. To accelerate its impact, CRISPR Therapeutics has established strategic collaborations with leading biopharmaceutical partners, including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California. To learn more, visit www.crisprtx.com.

Investor Contact:
+1-617-307-7503
[email protected]

Media Contact:
+1-617-315-4493
[email protected]

Many investors who follow CRISPR Therapeutics (CRSP +0.22%) still treat it as a gene-editing story. That makes sense, as the company's only commercialized drug, Casgevy, is a gene-editing therapy. But this biotech's ambitions are bigger than that modality alone.

In May 2025, it paid $95 million up front to Sirius Therapeutics for CTX611, a clinical-stage long-acting small interfering RNA (siRNA) therapy that's being investigated for the prevention of thrombosis and thromboembolic disorders. That often-overlooked program may turn out to be a major asset for the company; here's why.

Image source: Getty Images.

This program is an asymmetrical bet In a nutshell, CTX611 works by silencing the messenger RNA (mRNA) for the coagulation enzyme Factor XI in the liver. That silencing reduces the production of the coagulation factor, making the patient's blood less likely to form dangerous blood clots.

With CTX611, it may be possible to blunt the production of the coagulation factor without causing detrimental side effects like excessive bleeding, which is a problem with traditional anticoagulant medicines like warfarin. CRISPR Therapeutics' candidate is engineered for twice-yearly subcutaneous dosing, which may also be an advantage compared to alternatives that require daily pills or monthly antibody infusions.

One important thing to note is that CRISPR Therapeutics made a far smaller up-front commitment than its bigger competitors for a shot at the same market. Novartis paid up to $3.1 billion in 2025 to own abelacimab, a monthly antibody targeting the same coagulation factor. Eliquis, the leading anticoagulant (owned by Pfizer and Bristol Myers Squibb), alone generated $14.4 billion in revenue in 2025. While CRISPR Therapeutics owes Sirius additional milestone payments that could bring the deal's total value to over $800 million, and it'll also bear half of all development costs, that's still a fraction of what Novartis committed.

Today's Change

(

0.22

%) $

0.11

Current Price

$

50.34

There's a catch Competition in the anticoagulant segment is fierce and growing.

Aside from biologics being tested by players like Novartis, and improved small-molecule drugs (which build on the successes of the prior generation of those medicines) being tested by other big pharma businesses, CTX611 is not the only siRNA therapy targeting Factor XI. Suzhou Ribo Life Science's candidate, vortosiran, reached the clinic first, and is presently in phase 2b trials.

Even if CRISPR Therapeutics manages to get its program approved and out the door first, it'll immediately be competing intensely based on its therapy's cost, convenience, safety, availability, and effectiveness. The takeaway is that CTX611 is most likely to be a follower, rather than a category leader.

Nonetheless, given that the biotech only made $1.4 million in revenue in the first quarter of 2026 (though that figure excludes its 40% share of Casgevy revenue due to the way its collaboration is structured), even getting a foothold in the anticoagulants market with this candidate could be immensely impactful for the stock. The biotech expects to deliver an update on the program's progress through its phase 2 clinical trials in the second half of this year, so stay tuned.

Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bristol Myers Squibb, CRISPR Therapeutics, and Pfizer. The Motley Fool has a disclosure policy.

For years, CRISPR Therapeutics (CRSP +0.22%) has been the type of stock investors might call a home run swing. The company develops medicines using gene-editing technologies to treat or cure serious conditions and diseases that traditional pharmaceutical drugs cannot.

The stock has generated good returns over time, but it's been a very bumpy ride at times. Today, CRISPR Therapeutics' stock trades at a fraction of its former price. However, Wall Street analysts see opportunity. On CNN Business, 58% of Wall Street analysts have rated CRISPR Therapeutics as a buy, with price targets signaling as much as 437% upside.

Here's a look at why analysts might be bullish.

Image source: The Motley Fool.

Commercial revenue is finally taking off CRISPR Therapeutics has been around for years, but it only recently commercialized its first product. Casgevy is a gene editing treatment co-developed with Vertex Pharmaceuticals to treat sickle cell disease and transfusion-dependent beta thalassemia. It's a one-time treatment tailored to each patient's edited DNA that functionally mutes the disease, coming as close to a functional cure as you can get.

It takes time to treat patients with Casgevy; patients submit a sample of their DNA, which is edited and then reintroduced into the patient. CRISPR and Vertex received FDA approval in late 2023. Yet only 64 patients received Casgevy infusions in 2025.

The company generated $4.1 million in sales last year. Analysts see revenue growing to $43.9 million this fiscal year and to $151.6 million next fiscal year.

One-time treatments don't generate recurring revenue, but there's a vast patient pool. CRISPR estimates 60,000 eligible patients are in the United States and other countries where the therapy is approved.

Today's Change

(

0.22

%) $

0.11

Current Price

$

50.34

CRISPR stock is absurdly cheap -- if you look at the big picture The stock doesn't look cheap at first glance. At its current market cap of $5.4 billion, CRISPR still trades at roughly 35 times next year's revenue estimates. But things change as you zoom out.

CRISPR has a strong pipeline, with five other therapies at various stages of clinical trials. If even one or two of those hit, it's a potential game changer. CRISPR wholly owns four of those five therapies, meaning significantly more financial upside if they make it through trials and to the market. In the meantime, Casgevy will continue to grow and create a financial floor for the company.

Some of the world's largest pharmaceutical companies are worth hundreds of billions of dollars. CRISPR Therapeutics has a long way to go, but the ceiling is quite high. Gene editing produced a revolutionary treatment in Casgevy, and it can duplicate that success in some of the harshest known diseases, where traditional pharmaceuticals have failed.

This is all still highly speculative, so investors should tread carefully. That said, CRISPR's relatively modest market cap and its first big win with Casgevy make the stock a potential home run over the next decade, worth buying and holding to take that swing. If things go well, that 437% upside from analysts doesn't look so outlandish at all.

CRISPR Therapeutics AG (CRSP) Presents at Jefferies Global Healthcare Conference 2026 Transcript

By all accounts, CRISPR Therapeutics (CRSP +0.22%) shares should be soaring. The company shares rights to one of the healthcare industry's very few approved gene-editing therapies, and has several more in the works.

Initial interest in its sole approved treatment is solid, too. Despite a steep price tag of $2.2 million per patient, over 500 people have at least begun using its single marketed therapy, one that was only approved in late 2023. And the debt-light $5.5 billion company has over $2.4 billion worth of liquidity, while analysts' consensus price target of $80.62 is 40% above the stock's current price.

Yet shares of the biopharma are seemingly stuck, unable to make any progress since 2022, even though its story has become so much more compelling during this time frame. What gives? Nothing that's really all that surprising, all things considered. And the stock's stagnation isn't a reason not to take a swing on it sooner rather than later.

But first things first. What exactly does this company do?

Today's Change

(

0.22

%) $

0.11

Current Price

$

50.34

CRISPR Therapeutics is obviously a biopharma name -- but it's a unique one. Co-founder Emmanuelle Charpentier and her research collaborator Jennifer Doudna co-invented the CRISPR/Cas9 gene-editing technique. It not only became the scientific basis for the company's drugs, but also won the pair a Nobel Prize in Chemistry in 2020.

But what is "CRISPR?" It's an acronym for "clustered regularly interspaced short palindromic repeats" -- a pattern observed within the antiviral DNA of small organisms like bacteria. Cas9 is an enzyme that splices a DNA chain in a very specific spot identified by guide RNA, allowing a damaged or faulty sequence to be replaced with a corrected sequence created by CRISPR technology.

Its potential uses are considerable, although CRISPR Therapeutics got the ball rolling with a relatively modest one. Its gene-editing therapy Casgevy, approved in 2023, is aimed at the inherited blood disorders sickle cell disease and beta thalassemia.

Bigger and better targets are in the works, though. The company's clinical pipeline includes trials of the same gene-editing approach to treat cardiovascular disease and diabetes, while ailments like cystic fibrosis, muscular dystrophy, and hypertension are longer-term prospects currently in preclinical studies.

Why investors are remaining on the sidelines Sounds good. So why isn't the stock moving? There are a handful of factors working against it here. One of them is the price tag of the treatment: At $2.2 million a pop, insurers are obviously requiring a considerable amount of justification.

Another stumbling block is the sheer complexity of the treatment process, which is slowing revenue reporting. Casgevy isn't a simple injection that's mass-manufactured; it's customized for each patient using a sample of their own blood stem cells, and can take months from start to finish. CRISPR Therapeutics doesn't get to book any patient revenue until the end of the treatment process.

Image source: Getty Images.

Investors may also be disappointed in what seem like agonizingly poor results and sizable losses right now and for the foreseeable future. Although next year's projected revenue of $151.7 million is a marked improvement over this year's likely top line of $44 million, that's still weak for a $5.5 billion company that developed a breakthrough treatment, with more game-changing drugs in the works. 

Another factor is Vertex Pharmaceuticals (VRTX 0.50%), its partner in the Casgevy business. (Vertex has 60% of the partnership, compared to its own 40%.) CRISPR Therapeutics needs Vertex's sample-collection and treatment centers. The two companies are splitting profits and losses on the drug, though, and like most young drugs, this one remains unprofitable to start. Although Vertex has other revenue-bearing and profitable products in its portfolio, CRISPR Therapeutics doesn't -- at least, not yet.

Then there's the recent fundraiser, which may not be the last one for a while. In March, CRISPR Therapeutics issued $600 million in notes that could be converted into over 7.8 million shares of stock, potentially diluting the 96.5 million shares currently outstanding. This paper essentially acts like debt in the meantime, requiring the company to make semi-annual interest payments.

This is the norm for up-and-coming biopharma companies That's a lot of stumbling blocks -- paired with a pipeline that's promising, but far from guaranteed to produce a bunch of approved drugs in the near or distant future. It's not difficult to see why interested investors are balking.

The thing is, there's nothing particularly unusual about any of this for an up-and-coming biopharma name. They all tend to suffer losses early on, so they all need to regularly raise new capital. No start-up pharma outfit can guarantee that every clinical trial will turn into an approved, marketable drug. Neither can the biggest names in the pharmaceutical business.

So there's risk here, to be sure, but it's commensurate with the potential reward. Mordor Intelligence expects the nascent gene-editing therapy market to grow at an average annual pace of 16% through 2031, when it will be worth nearly $26 billion per year (although this outlook arguably still understates the potential of gene-editing treatments).

The bottom line? If you can stomach the above-average risk and stick with it for a while, there's meaningful upside here. As a 12-month target, the consensus analyst price target of $80.62 is just the beginning. While the company and the stock make forward progress, look for this bullishness to grow. The tough part is just waiting for something -- or someone -- to get the ball rolling in the meantime. It seems like most investors are waiting on the sidelines for a clear catalyst.

Of course, all too often, waiting for such a catalyst means you'll miss out on some sizable early gains. 

With all that said, given the strength of its intellectual property and pipeline, there's also an argument to be made that CRISPR Therapeutics is a candidate for acquisition by a bigger player, one with deeper developmental pockets and more marketing firepower. But that's still not enough reason to step into this stock.

In the latest close session, CRISPR Therapeutics AG (CRSP - Free Report) was down 3.9% at $49.47. The stock's change was less than the S&P 500's daily loss of 1.62%. Elsewhere, the Dow saw a downswing of 1.87%, while the tech-heavy Nasdaq depreciated by 1.98%.

The company's stock has dropped by 2.56% in the past month, falling short of the Medical sector's gain of 5.04% and the S&P 500's loss of 0.03%.

The investment community will be closely monitoring the performance of CRISPR Therapeutics AG in its forthcoming earnings report. On that day, CRISPR Therapeutics AG is projected to report earnings of -$1.11 per share, which would represent year-over-year growth of 13.95%. At the same time, our most recent consensus estimate is projecting a revenue of $9.28 million, reflecting a 942.7% rise from the equivalent quarter last year.

For the full year, the Zacks Consensus Estimates are projecting earnings of -$4.92 per share and revenue of $38.88 million, which would represent changes of +23.96% and +1007.58%, respectively, from the prior year.

Investors might also notice recent changes to analyst estimates for CRISPR Therapeutics AG. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.

Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, there's been a 3.42% rise in the Zacks Consensus EPS estimate. CRISPR Therapeutics AG presently features a Zacks Rank of #3 (Hold).

The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 155, putting it in the bottom 37% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.

CRISPR Therapeutics AG (CRSP - Free Report) ended the recent trading session at $50.27, demonstrating a +1.68% change from the preceding day's closing price. This move lagged the S&P 500's daily gain of 1.75%. Elsewhere, the Dow saw an upswing of 1.86%, while the tech-heavy Nasdaq appreciated by 2.54%.

Heading into today, shares of the company had lost 6.27% over the past month, lagging the Medical sector's gain of 3.73% and the S&P 500's loss of 1.63%.

The investment community will be paying close attention to the earnings performance of CRISPR Therapeutics AG in its upcoming release. The company is expected to report EPS of -$1.11, up 13.95% from the prior-year quarter. In the meantime, our current consensus estimate forecasts the revenue to be $9.28 million, indicating a 942.7% growth compared to the corresponding quarter of the prior year.

Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$4.9 per share and revenue of $38.88 million, indicating changes of +24.27% and +1007.58%, respectively, compared to the previous year.

It is also important to note the recent changes to analyst estimates for CRISPR Therapeutics AG. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.

Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.

The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 3.99% higher within the past month. CRISPR Therapeutics AG is currently sporting a Zacks Rank of #3 (Hold).

The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 153, positioning it in the bottom 38% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.